No Prescription |
 |
 | ||
|
Flomaxtra Flomax |
|
| ||
No Prescription » Prescription Drugs 7 » Flomaxtra Flomax FLOMAXTRA« is a registered trademark of Astellas Pharma Europe B.V.INDICATIONS:For the relief of lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH).DOSAGE AND ADMINISTRATIONOne tablet daily.The tablet must be swallowed whole and not be broken crunched or chewed as this compromises the prolonged release properties of the tablet for the active ingredient.FLOMAXTRA« can be taken on an empty stomach or before with or after food. Buy Flomaxtra Flomax and other Prescription Drugs 7 products online at Medstore. 5519
About Flomaxtra Flomax: Product Type: Prescription Drugs 7 Flomaxtra ( Flomax Generic Tamsulosin ) Flomaxtra (Flomax Generic Tamsulosin) Flomax Generic Tamsulosin 0.4mg 30 Capsules Flomax Generic Tamsulosin Flomaxtra
View more Prescription Drugs 7 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
